2024-04-15 15:52:00
In the Phase III Starglo study, the Roche Group succeeded in extending the survival of the treated blood cancer patients. The goals of the study have been achieved, according to a communiqué on Monday.
The study treated patients who suffered from so-called relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who had already received at least one previous line of therapy and were not eligible for an autologous stem cell transplant. In the study, they received Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx).
“People with this aggressive lymphoma who experience relapse or disease progression following initial treatment have limited options – particularly those who are ineligible for stem cell transplantation,” said Levi Garraway, chief medical officer and head of global product development from Roche, quoted in the release.
Columvi was reported to be the first fixed-duration bispecific antibody to receive accelerated approval from the US Food and Drug Administration (FDA) and conditional marketing authorization from the European Commission for the treatment of patients with R/R DLBCL following two or more lines of systemic therapy.
Roche shares responded with small gains following temporary price fluctuations. In SIX trading it was ultimately quoted 0.04 percent higher at 225.10 francs.
Basel (awp)
1713216676
#Roche #shares #friendly #research #success #cancer #drug #Columvi
